HOME >> MEDICINE >> NEWS
Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM

West Haven, CT and Emeryville, CA January 11, 2007 -- Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the New England Journal of Medicine has published their pivotal Phase III trial demonstrating that Nexavar (sorafenib) tablets doubled median progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), or kidney cancer. The data, as assessed by independent radiologic review, are from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) the largest randomized controlled trial ever conducted in advanced RCC.

"Historically, patients with kidney cancer have had limited treatment options and there has been a particularly critical need for new therapies to help patients with advanced disease," said co-principal investigator Ronald Bukowski, M.D., Director of the Experimental Therapeutics Program of The Cleveland Clinic Taussig Cancer Center in Cleveland, OH. "This landmark study demonstrated the efficacy, tolerability and clinical benefit of Nexavar, which has rapidly become a valuable weapon against this devastating disease."

Based on these data, Nexavar was granted U.S. Food and Drug Administration (FDA) approval for the treatment of patients with advanced RCC, or kidney cancer, on December 20, 2005. Since then, Nexavar has been approved in nearly 50 countries.

"Nexavar was the first new drug approved for patients with advanced kidney cancer in over a decade," said Bill Bro, President and Chief Executive Officer of the Kidney Cancer Association (KCA). "With the advent of targeted therapies such as Nexavar, there has been remarkable change patients are experiencing improved outcomes without the toxic effects traditionally associated with chemotherapy."

Phase III Summary
More than 900 patients with advanced RCC were randomized one-to-one to receive either 400 mg Nexavar or placebo orally twice
'"/>


10-Jan-2007


Page: 1 2

Related medicine news :

1. Bayer launches Phase III clinical study of Trasylol in elective spinal fusion surgery
2. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
3. Program announced to improve care in developing areas for patients with blood disorders
4. AstraZeneca announces SYMBICORT is now available in the US
5. Weill Cornell Medical College announces gifts totaling $400M
6. GSK announces launch of largest ever Phase III trial in lung cancer treatment
7. World first medical treatment announced by researchers
8. Cure for hepatitis C announced by VCU researcher
9. Elsevier announces launch of Brain Stimulation
10. TWAS, illycaff announce Trieste Science Prize winners 2007
11. AIUM announced Endowment for Education and Research grant recipients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/1/2020)... ... September 01, 2020 , ... ... completed $3 million convertible note financing, which will be used to accelerate the ... funds from this financing, the company will continue to expand its customer base ...
(Date:9/1/2020)... , ... September 01, 2020 , ... As fall and ... the Cohn Health Institute has taken this time to expand and grow ... its 30th Anniversary, the Cohn Health Institute will be relaunching its brand new website, ...
(Date:8/31/2020)... ... August 31, 2020 , ... Cardiothoracic surgeons at Allegheny General ... Carnegie Mellon University (CMU) to develop a new heart monitoring device designed to ... surgery. , The AGH/CMU team was recently awarded a “Trailblazer” grant from the ...
(Date:8/31/2020)... ... August 31, 2020 , ... Just found out your dear friend has cancer? , It’s ... friend or family member shares their diagnosis. Once the shock wears off, the questions and ... thing? What are the best ways to help? Words are failing me. I’m scared. I ...
(Date:8/31/2020)... ... ... Want to get moving, break up your routine, and make a difference right ... its fourth annual STEPtember campaign in the United States to raise funds and awareness ... at this moment — encouraging people to move in the ways that work for ...
Breaking Medicine News(10 mins):
(Date:9/1/2020)... ... 01, 2020 , ... September is National Ovarian Cancer Awareness Month. Ovarian ... other cancer of the female reproductive system. The American Cancer Society estimates that ... women will die from this disease. Throughout the month of September, Women’s Excellence ...
(Date:8/31/2020)... ... ... If you live in New York City you will always pay more for these two ... of supply and demand, but are plastic surgeons in New York worth the premium prices ... that make the four-hour trip to have expert aesthetic treatments by some of the best ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... guide, has named Cloudticity a Gold winner in the 15th Annual 2020 Network ... recogniti o ns from Network Products Guide honoring achievements of world’s ...
Breaking Medicine Technology:
Cached News: